We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Gastrointestinal PCR Assay Offers Rapid, Culture-Free Pathogen Identification

By LabMedica International staff writers
Posted on 17 Apr 2023
Print article
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)

Gastroenteritis involves inflammation of the stomach and intestines' lining, typically characterized by diarrhea and/or vomiting. Gastrointestinal pathogens can cause life-threatening diseases, especially among children, immunosuppressed individuals, and the elderly. While most cases resolve within days, severe or persistent cases may necessitate hospitalization. Testing stool samples for potential causative agents—bacteria, viruses, parasites, and toxins—creates a substantial diagnostic burden in healthcare facilities. Now, a new syndromic panel for gastrointestinal infections that identifies 26 gastroenteritis-causing pathogens, including bacteria, viruses, parasites, and related toxins, aims to streamline routine procedures and enhance diagnostic efficiency.

Bruker Corporation’s (Billerica, MA, USA) new LiquidArray Gastrointestinal is a syndromic panel for gastrointestinal infections. The assay employs LiquidArray, a next-generation multiplexing technology, to detect up to 26 pathogens from stool samples using a two-well format that supports routine laboratory throughput needs. Introduced on the high-precision FluoroCycler XT thermocycler, LiquidArray merges innovative probe and thermocycling technologies with results-at-a-glance visualization for simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware XT-IVD generates easy-to-understand results, expediting clinical decisions.

LiquidArray Gastrointestinal is validated on the GenoXtract fleXT, a dependable, automated system for extracting nucleic acid from patient samples and setting up PCR plates. Barcode-supported robotic sorting minimizes manual intervention. Validated processing of LiquidArray Gastrointestinal on the GenoXtract fleXT offers a convenient walk-away solution tailored for dynamic laboratory environments. This equips high-throughput clinical labs with a fully integrated workflow from sample to result. The test is validated for use with stool samples, and a stool buffer developed for LiquidArray Gastrointestinal enables stabilization and storage of samples to be tested. The kit includes reagents for up to 48 reactions.

“The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run,” said Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division.

Related Links:
Bruker Corporation 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.